Theranostics in Renal Cell Carcinoma: A Systematic Review
Author Information
Author(s): Jóźwik-Plebanek Katarzyna, Saracyn Marek, Kołodziej Maciej, Kamińska Olga, Durma Adam Daniel, Mądra Weronika, Gniadek-Olejniczak Katarzyna Agnieszka, Dedecjus Marek, Kucharz Jakub, Stec Rafał, Kamiński Grzegorz
Primary Institution: Military Institute of Medicine—National Research Institute, Warsaw, Poland
Hypothesis
Is PSMA PET/CT a useful and/or prognostic tool in imaging diagnostics of clear cell renal cell carcinoma?
Conclusion
PSMA PET/CT shows high sensitivity in detecting clear cell renal cell carcinoma lesions and can influence treatment strategies.
Supporting Evidence
- PSMA PET/CT has shown high sensitivity in detecting ccRCC lesions.
- PSMA PET/CT can influence clinical decision-making in 13–43.8% of patients.
- PSMA expression correlates with patient prognosis in ccRCC.
- PSMA PET/CT outperforms conventional imaging methods in many cases.
- Limited studies exist comparing the efficacy of different PSMA ligands.
Takeaway
This study looks at how a special type of imaging can help doctors find and treat kidney cancer better.
Methodology
A systematic literature review was conducted following PRISMA guidelines, analyzing studies on PSMA PET/CT in clear cell renal cell carcinoma.
Potential Biases
Most studies were single-centered and retrospective, which may introduce bias.
Limitations
The review is limited by the small number of studies and the lack of large-scale prospective trials.
Participant Demographics
The studies included patients diagnosed with clear cell renal cell carcinoma.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI, 0.81–0.98
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website